Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.

Kwak, Soo Heon; Han, Kyung Ah; Kim, Kyung-Soo; Yu, Jae Myung; Kim, EunSook; Won, Jong Chul; Kang, Jun Goo; Chung, Choon Hee; Oh, Seungjoon; Choi, Sung Hee; Won, Kyu Chang; Kim, Sin Gon; Cho, Seung Ah; Cho, Bo Young; Park, Kyong Soo

Kwak, Soo Heon; Han, Kyung Ah; Kim, Kyung-Soo; Yu, Jae Myung; Kim, EunSook; Won, Jong Chul; Kang, Jun Goo; Chung, Choon Hee; Oh, Seungjoon; Choi, Sung Hee; Won, Kyu Chang; Kim, Sin Gon; Cho, Seung Ah; Cho, Bo Young; Park, Kyong Soo.

Affiliation

Kwak SH; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Han KA; Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University, Seoul, South Korea.
Kim KS; Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
Yu JM; Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea.
Kim E; Department of Internal Medicine, Ulsan University Hospital, College of Medicine University of Ulsan, Ulsan, South Korea.
Won JC; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, South Korea.
Kang JG; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea.
Chung CH; Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju, South Korea.
Oh S; Department of Internal Medicine, Kyung Hee University Hospital, Seoul, South Korea.
Choi SH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Won KC; Department of Internal Medicine, Yeungnam University Medical Center, Daegu, South Korea.
Kim SG; Department of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea.
Cho SA; Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.
Cho BY; Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.
Park KS; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.

Diabetes Obes Metab ; 25(7): 1865-1873, 2023 07.

Article de En | MEDLINE | ID: mdl-36872067

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Diabète de type 2 / Inhibiteurs du cotransporteur sodium-glucose de type 2 Type d'étude: Clinical_trials Limites: Humans Pays/Région comme sujet: Asia Langue: En Journal: Diabetes Obes Metab Sujet du journal: ENDOCRINOLOGIA / METABOLISMO Année: 2023 Type de document: Article Pays d'affiliation: Corée du Sud

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google